Key result
Recombinant von Willebrand factor prophylaxis is cost-saving compared to plasma-derived VWF across all willingness-to-pay thresholds for severe von Willebrand disease in the US.
Why the study?
Is prophylaxis with recombinant von Willebrand factor cost-effective compared to plasma-derived von Willebrand factor in patients with severe Von Willebrand disease?
Is prophylaxis with recombinant von Willebrand factor cost-effective compared to plasma-derived von Willebrand factor in patients with severe Von Willebrand disease?
Recombinant von Willebrand factor is a cost-saving prophylactic strategy compared to plasma-derived factor for severe von Willebrand disease in the US.
Answers are grounded in this paper and cite their sources.
May support recombinant VWF prophylaxis in severe VWD on cost grounds; leaves open real-world validation of modeled savings.
We evaluated the cost-effectiveness of prophylaxis with recombinant von Willebrand factor (rVWF) vs with plasma-derived von Willebrand factor (pdVWF) for patients with severe Von Willebrand disease. We found that rVWF is a cost-saving factor replacement compared with pdVWF across all willingness-to-pay thresholds in the United States.
No takes yet. Share an insight, caveat, or question.
Waldron et al. (2024) studied this question. Recombinant von Willebrand factor prophylaxis is cost-saving compared to plasma-derived VWF across all willingness-to-pay thresholds for severe von Willebrand disease in the US.
Synapse has enriched 10 related papers. Consider them for comparative context: